Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma(EPCORE™ NHL-1) | active not recruiting | Phase 1 / Phase 2 | 666 | GenmabINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)(EPCORE™ NHL-3) | active not recruiting | Phase 1 / Phase 2 | 78 | GenmabINDUSTRY | 1 |
| Sep 9, 2026 |
| clinicaltrials |
| NCT04899908 | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | recruiting | Phase 2 | 134 | Brigham and Women's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05925530 | Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)(MDT-BRIDGE) | active not recruiting | Phase 2 | 142 | AstraZenecaINDUSTRY | 11 | Sep 9, 2026 | clinicaltrials |
| NCT06315010 | Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis(REPOSE) | recruiting | Phase 2 | 20 | MedSIROTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | recruiting | Phase 1 / Phase 2 | 327 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation(KRAScendo 170) | recruiting | Phase 1 / Phase 2 | 320 | Hoffmann-La RocheINDUSTRY | 18 | Sep 8, 2026 | clinicaltrials |
| NCT05801029 | A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations(OSTARA) | active not recruiting | Phase 2 | 60 | AstraZenecaINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT07130786 | Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases | recruiting | Phase 2 | 150 | Ayal A. Aizer, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07132190 | Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction | recruiting | Phase 2 | 60 | Ayal A. Aizer, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07367529 | A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection | recruiting | Phase 1 / Phase 2 | 465 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07718243 | Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC(BLAZE) | recruiting | Phase 1 / Phase 2 | 62 | Institute of Cancer Research, United KingdomOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807722 | Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC | not yet recruiting | Phase 2 | 29 | Hubei Cancer HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07808138 | RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer(RADICAL-IO) | not yet recruiting | Phase 2 | 30 | The Netherlands Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT02642042 | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05198830 | Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07012031 | Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | recruiting | Phase 1 / Phase 2 | 480 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07640932 | Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer(LUPINE) | not yet recruiting | Phase 2 | 69 | Yonsei UniversityOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07803848 | Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status(SPACE-T) | recruiting | Phase 2 | 57 | AIO-Studien-gGmbHOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03178552 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST) | active not recruiting | Phase 2 / Phase 3 | 1,000 | Hoffmann-La RocheINDUSTRY | 27 | Sep 3, 2026 | clinicaltrials |
| NCT04699838 | Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 2 | 30 | Muhammad FurqanOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04892953 | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | recruiting | Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05374603 | Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC(SOUND) | active not recruiting | Phase 2 | 47 | AstraZenecaINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05673187 | Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status(ADEPPT) | active not recruiting | Phase 2 | 68 | ETOP IBCSG Partners FoundationNETWORK | 6 | Sep 3, 2026 | clinicaltrials |
| NCT07089199 | Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study(TitAN) | recruiting | Phase 2 | 34 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07491497 | A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | recruiting | Phase 1 / Phase 2 | 160 | TRIANA Biomedicines, Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802834 | Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC | not yet recruiting | Phase 2 | 42 | Stanford UniversityOTHER | 0 | Sep 3, 2026 | clinicaltrials |
| NCT06043817 | First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | recruiting | Phase 1 / Phase 2 | 345 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06567015 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs(STX-241 FIH) | recruiting | Phase 1 / Phase 2 | 171 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT07138755 | The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients | recruiting | Phase 2 | 35 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07293247 | A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment | recruiting | Phase 2 | 164 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07543172 | CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer | not yet recruiting | Phase 2 | 29 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07622186 | A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 150 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07798947 | A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC | not yet recruiting | Phase 2 | 120 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03600701 | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07355231 | Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI(GuidedRT) | not yet recruiting | Phase 1 / Phase 2 | 10 | Xemed LLCINDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT07486817 | Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab | recruiting | Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07789912 | BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies(BRAVO-LM) | not yet recruiting | Phase 2 | 40 | University of MiamiOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07796438 | Low-Frequency rTMS for In-Hospital Sleep Disturbance in Advanced NSCLC | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Sep 1, 2026 | clinicaltrials |
| NCT02133196 | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04736173 | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer(ARC-10) | active not recruiting | Phase 2 | 169 | Arcus Biosciences, Inc.INDUSTRY | 10 | Aug 31, 2026 | clinicaltrials |
| NCT05013450 | Dupilumab_Metastatic NSCLC | active not recruiting | Phase 1 / Phase 2 | 33 | Thomas MarronOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05460273 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | active not recruiting | Phase 1 / Phase 2 | 119 | AstraZenecaINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05830058 | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma | recruiting | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07070440 | DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) | recruiting | Phase 1 / Phase 2 | 180 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07079475 | Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) | recruiting | Phase 1 / Phase 2 | 220 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07322341 | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer | recruiting | Phase 2 | 32 | University of WashingtonOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05949606 | A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 95 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials